Nurix Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) Transcript
Hey, good morning, everyone, and thanks for joining our first annual TPD summit. We view TPD as a very fascinating and broadly applicable modality that continues to evolve at a very rapid pace. So, we published our updated white paper last week and our discussions today with industry leaders look to dive a little bit deeper on some of those hot topics of the day.
So, our first panel this morning, we'll be discussing overcoming resistance with targeted protein degradation. And I'm going to turn it over to a man who needs no introduction. My colleague, Jim Birchenough who will be hosting this panel. So, Jim, please take it away.
Thanks, Derek. Really appreciate all the work you've done in the TPD space and for setting up this summit. We've got a terrific panel for this first topic, as Derek suggested, overcoming resistance with targeted protein degradation. We have with us this morning, Arthur Sands, who's the CEO of Nurix since 2014. Most of you will know, Arthur, as the co
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |